Latest news

• Pfizer files third-gen ALK inhibitor for lung cancer

  of competitive pressure from Roche’s fast-growing rival Alecensa (alectinib), a second-generation inhibitor that is well-tolerated and has the added benefit of penetrating the brain, which can help ... Alecensa saw sales double to reach around $385m in

• Roche faces biosimilar blitz in 2018

  Last year, Ocrevus, Tecentriq, Perjeta and Alecensa sales drove a 5% growth for Roche, along with label extensions for existing products and approvals for new medicines Ocrevus and Hemlibra in the ... US. Schwan added: “I am particularly pleased with

• Roche gets FDA OKs for Alecensa and Zelboraf

  Roche gets FDA OKs for Alecensa and Zelboraf. Gains US licences for first-line use in lung cancer and a rare blood cancer. ... Approval of Alecensa for front-line use in Europe is expected in the next few weeks after it was recommended by the Committee

• Roche wins CHMP nod for Alecensa licence extensions

  Roche wins CHMP nod for Alecensa licence extensions. Lung cancer monotherapy set for a broader European label. ... European regulatory advisors have given their backing to new uses of Roche’s lung cancer drug Alecensa (alectinib).

• Amgen's Mvasi is first FDA-approved cancer biosimilar

  Roche is also in the midst of a fertile launch period for new medicines, with a clutch of new drugs - including Cotellic (cobimetinib) for melanoma, Alecensa (alectinib) for lung cancer, leukaemia